AcquisitionOther
SERB Pharmaceuticals acquired Y-mAbs Therapeutics, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
SERB Pharmaceuticals -> Y-mAbs Therapeutics, Inc. · approximately $412 million
Acquisition includes Naxitamab-gqgk, furthering SERB's rare oncology product portfolio.
Open source record (SEC) ↗